Medical News Hour

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Deferoxamine Mesylate for Injection, USP, in two dosage strengths.

Original post:

APP Pharmaceuticals Receives Approval For Deferoxamine Mesylate For Injection, USP

Related posts:

1. APP Pharmaceuticals Receives Approval For The First Generic Chlorothiazide Sodium For Injection, USP
2. Teva Receives Final Approval For Generic Prevacid(R) Delayed-Release Capsules
3. Mylan’s Matrix Receives Tentative FDA Approval Under PEPFAR For Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Tablets
4. Winston Laboratories, Inc. Receives Notice Of Non-Compliance In Canada For Its New Drug Submission Of CIVANEX To Treat Osteoarthritis
5. Anika Therapeutics Receives European CE Mark Approval For "ELEVESS Light"